12:50 AM EDT, 05/12/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our target price at $7, based on our DCF analysis. We narrow our 2025 adjusted LPS view to -$0.56 from -$1.50 and our 2026 adjusted LPS estimate to -$0.65 from -$1.17. TXG painted a mixed outlook for the remainder of 2025, in our view, despite a top line beat in Q1 driven by a one-off payment. Revenue rose by 10% Y/Y, due largely to the $17M gain from a patent litigation settlement. Excluding this settlement, TXG's revenue declined by 2% Y/Y due to a sharp 42% Y/Y decrease in instrument sales (both Chromium and Spatial) as the business continues to face headwinds, particularly in the academic and government research funding environment. Management has implemented cost-cutting measures, including an 8% reduction in the global workforce and a plan to decrease operating expenses. Yet, with 40%-50% of TXG's revenue supported by U.S. academic and government clients, we expect ongoing uncertainties to continue to pressure TXG's sales performance in the near term.